What is Refined Technologies?
Refined Technologies, LLC operates at the intersection of laboratory efficiency and advanced bioprocessing. The company is recognized for its innovative product suite, most notably the CORe Cell Culture System and CleanLine Connectors. These solutions are engineered to address the rigorous demands of cell biology and bioprocessing environments, providing essential connector assemblies and accessories that streamline complex workflows. By focusing on high-precision hardware, Refined Technologies serves a critical role in the life sciences supply chain, enabling researchers and industrial bioprocessors to maintain sterility and operational consistency. Their market strategy emphasizes the integration of modular, high-performance components into existing laboratory architectures, thereby reducing downtime and enhancing experimental reproducibility.
How much funding has Refined Technologies raised?
Refined Technologies has raised a total of $2M across 1 funding round:
Debt
$2M
Debt (2020): $2M with participation from PPP
Key Investors in Refined Technologies
PPP
Public-Private Partnership
What's next for Refined Technologies?
With this major strategic investment, Refined Technologies is expected to pivot toward aggressive market expansion and product diversification. The capital will likely be deployed to enhance manufacturing capacity for the CleanLine Connector line and to support the R&D initiatives required for next-generation bioprocessing hardware. As the biotechnology sector continues to prioritize scalable, automated solutions, Refined Technologies is positioned to capture additional market share by addressing the persistent bottlenecks in cell culture workflows. Future growth will likely be driven by strategic partnerships with large-scale biopharmaceutical manufacturers and continued presence at key industry forums to solidify their reputation as a leader in laboratory efficiency.
See full Refined Technologies company page
